PAVmed Stock
PAVmed Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Lishan Aklog
- Employees
- 41
- Market cap
- $19 M
- IPO
- 27/07/2016
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and…
PAVmed stock: price history
1D
-0.4%
1W
-13.6%
1M
-38.5%
6M
-73.6%
YTD
-63.6%
1Y
-83.7%
2Y
-92.3%
5Y
-99.9%
10Y
-100.0%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~31% stronger price swings than usual
Ask the agents about PAVmed
Analyst assessment of PAVmed
0
STRONG BUY
2
BUY
1
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 27/08/2026
PAVmed stock metrics
P/E
-0.15
P/B
0.43
EV/EBITDA
-1.99
RETURN ON EQUITY
-15.4%
NET MARGIN
-16,315.2%
DEBT/EQUITY
0.49
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
51.3%
FLOAT SHARES
4,103,815
AVG. DAILY VOLUME (30D)
26,907
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about PAVmed stock
What does PAVmed do?
PAVmed Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Lishan Aklog, the company employs around 41 people.
The IPO was on 27/07/2016; the stock trades on NASDAQ under the ticker PAVM.
What do analysts say about PAVmed stock?
3 analysts rate the stock, the consensus is Buy (as of 27/08/2026).
This is an external assessment, not a statement by Market Jury.
When does PAVmed report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 31% stronger than usual.
Does PAVmed pay a dividend?
No, PAVmed currently does not pay a dividend.
Which stocks are comparable to PAVmed?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get PAVmed stock analyzed?
Clicking "Analyze stock" lets five strategies assess PAVmed against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.